Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

NCT02162667 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

562

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Carcinoma of Breast

Interventions

DRUG: Trastuzumab

Sponsor

Celltrion

Collaborators

[object Object]